Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Total	Total LianBio Shareholders’ Equity (Deficit)	Ordinary Shares	Additional Paid in Capital	Accumulated Other Comprehensive (Loss) Income	Accumulated Deficit	Non- Controlling Interest
Beginning balance (in shares) at Dec. 31, 2021			107,275,458
Beginning balance at Dec. 31, 2021	$ 387,336	$ 353,562	$ 2	$ 713,269	$ 526	$ (360,235)	$ 33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,669	4,669		4,669
Receivable from related party	1,710	1,710		1,710
Net loss	(27,726)	(27,726)				(27,726)
Comprehensive income (loss)	(1,216)	(1,216)			(1,216)
Ending balance (in shares) at Mar. 31, 2022			107,275,458
Ending balance at Mar. 31, 2022	364,773	330,999	$ 2	719,648	(690)	(387,961)	33,774
Beginning balance (in shares) at Dec. 31, 2021			107,275,458
Beginning balance at Dec. 31, 2021	387,336	353,562	$ 2	713,269	526	(360,235)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(92,014)
Ending balance (in shares) at Sep. 30, 2022			108,353,831
Ending balance at Sep. 30, 2022	306,598	272,824	$ 2	728,915	(3,844)	(452,249)	33,774
Beginning balance (in shares) at Mar. 31, 2022			107,275,458
Beginning balance at Mar. 31, 2022	364,773	330,999	$ 2	719,648	(690)	(387,961)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,528	4,528		4,528
Exercise of options (in shares)			1,000,000
Exercise of warrants (in shares)			78,373
Net loss	(42,391)	(42,391)				(42,391)
Comprehensive income (loss)	(712)	(712)			(712)
Ending balance (in shares) at Jun. 30, 2022			108,353,831
Ending balance at Jun. 30, 2022	326,198	292,424	$ 2	724,176	(1,402)	(430,352)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,739	4,739		4,739
Net loss	(21,897)	(21,897)				(21,897)
Comprehensive income (loss)	(2,442)	(2,442)			(2,442)
Ending balance (in shares) at Sep. 30, 2022			108,353,831
Ending balance at Sep. 30, 2022	$ 306,598	272,824	$ 2	728,915	(3,844)	(452,249)	33,774
Beginning balance (in shares) at Dec. 31, 2022	107,043,924		107,043,924
Beginning balance at Dec. 31, 2022	$ 293,647	259,873	$ 2	732,476	(2,080)	(470,525)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,276	4,276		4,276
Issuance of restricted stock units (in shares)			120,251
Net loss	(24,045)	(24,045)				(24,045)
Comprehensive income (loss)	549	549			549
Ending balance (in shares) at Mar. 31, 2023			107,164,175
Ending balance at Mar. 31, 2023	$ 274,427	240,653	$ 2	736,752	(1,531)	(494,570)	33,774
Beginning balance (in shares) at Dec. 31, 2022	107,043,924		107,043,924
Beginning balance at Dec. 31, 2022	$ 293,647	259,873	$ 2	732,476	(2,080)	(470,525)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (69,705)
Ending balance (in shares) at Sep. 30, 2023	107,168,686		107,168,686
Ending balance at Sep. 30, 2023	$ 236,112	202,338	$ 2	745,786	(3,220)	(540,230)	33,774
Beginning balance (in shares) at Mar. 31, 2023			107,164,175
Beginning balance at Mar. 31, 2023	274,427	240,653	$ 2	736,752	(1,531)	(494,570)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,494	4,494		4,494
Issuance of restricted stock units (in shares)			3,434
Net loss	(21,621)	(21,621)				(21,621)
Comprehensive income (loss)	(1,795)	(1,795)			(1,795)
Ending balance (in shares) at Jun. 30, 2023			107,167,609
Ending balance at Jun. 30, 2023	255,505	221,731	$ 2	741,246	(3,326)	(516,191)	33,774
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	4,540	4,540		4,540
Issuance of restricted stock units (in shares)			1,077
Net loss	(24,039)	(24,039)				(24,039)
Comprehensive income (loss)	$ 106	106			106
Ending balance (in shares) at Sep. 30, 2023	107,168,686		107,168,686
Ending balance at Sep. 30, 2023	$ 236,112	$ 202,338	$ 2	$ 745,786	$ (3,220)	$ (540,230)	$ 33,774

LianBio 10-Q